IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.

Maarten D BremBart C JacobsWouter van RijsWillem Jan R FokkinkAnne P Tio-GillenChrista WalgaardPieter A van DoornHanna IJspeertMirjam van der BurgRuth Huizinga

Published in: Annals of clinical and translational neurology (2018)

High-dose IVIg treatment alters the distribution of B-cell subsets in the peripheral blood of GBS patients, suggesting de novo (oligo-)clonal B-cell activation. Very high numbers of plasmablasts after IVIg therapy may be a potential biomarker for fast clinical recovery.

Keyphrases

peripheral blood
high dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
low dose
peritoneal dialysis
stem cells
high glucose
case report
stem cell transplantation
bone marrow
mesenchymal stem cells
oxidative stress
endothelial cells
smoking cessation